Search | Clinical Trials Finder

Conditions: Large B-cell Lymphoma, DLBCL
Interventions: 89Zr-DFO-REGN3767, PET/CT; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Melanoma, Liver Metastases
Interventions: Nivolumab and Relatlimab, Melphalan; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 CL plus tiotropium bromide, Respimat® Inhaler; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 5
States / cities: Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HER2-positive Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Beverly Hills, California • San Francisco, California • Stanford, California + 9 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
Interventions: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137; Biological · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more

Conditions: Melanoma
Interventions: PDR001, LAG525, INC280, ACZ885, LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Advanced Cancer
Interventions: Relatlimab, Nivolumab, BMS-986205, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 5
States / cities: Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 16
States / cities: Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more

Conditions: Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions: INCAGN02385; Biological
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more

Conditions: Progressive Glioblastoma, Recurrent Glioblastoma
Interventions: Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 325
States / cities: Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more

Conditions: Urothelial Carcinoma
Interventions: retifanlimab, epacadostat, INCAGN02385, INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Metastatic Cancer, Solid Tumor, Lymphoma
Interventions: Sym021, Sym022, Sym023; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: Healthy
Interventions: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Interventions: Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone; Drug
Lead sponsor: Multiple Myeloma Research Consortium; Network
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more

Conditions: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Interventions: favezelimab/pembrolizumab, pembrolizumab, lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: New Haven, Connecticut • Boston, Massachusetts • New Brunswick, New Jersey + 5 more

Conditions: HIV-1-infection
Interventions: Biktarvy Tab; Drug
Lead sponsor: Southampton Healthcare, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Healthy
Interventions: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Melanoma
Interventions: Relatlimab, Nivolumab, Relatlimab + Nivolumab; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Tiotropium/Salmeterol Inhalation Powder in COPD

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting